

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3832832

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the NAME OF THE ASSIGNEE TO ISOMERASE THERAPEUTICS LTD AND TO SUBMIT AN UPDATED CORRECTED ASSIGNMENT FOR STEVEN KENDREW previously recorded on Reel 037728 Frame 0450. Assignor(s) hereby confirms the ASSIGNMENT.

**CONVEYING PARTY DATA**

Name	Execution Date
STEVEN JAMES MOSS	12/03/2015
MATTHEW ALAN GREGORY	12/03/2015
BARRIE WILKINSON	12/10/2015
STEVEN KENDREW	03/21/2016

**RECEIVING PARTY DATA**

<b>Name:</b>	ISOMERASE THERAPEUTICS LTD.
<b>Street Address:</b>	SUITE 9, SCIENCE VILLAGE
<b>Internal Address:</b>	CHESTERFORD RESEARCH PARK
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	CB10 1XL

**PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	14903190

**CORRESPONDENCE DATA**

**Fax Number:** (215)563-4044

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** (215) 563-4100

**Email:** docketclerk@ddhs.com

**Correspondent Name:** ROBERT C. NETTER, JR., PH.D., J.D.

**Address Line 1:** 1601 MARKET STREET

**Address Line 2:** SUITE 2400

**Address Line 4:** PHILADELPHIA, PENNSYLVANIA 19103

<b>ATTORNEY DOCKET NUMBER:</b>	5078-P06279US00
<b>NAME OF SUBMITTER:</b>	ROBERT C. NETTER, JR., PH.D., J.D.
<b>SIGNATURE:</b>	/Robert C. Netter, Jr./

<b>DATE SIGNED:</b>	04/15/2016
---------------------	------------

**Total Attachments: 11**

- source=CoverSheet#page1.tif
- source=ISO-P1742PCT IP102 Executed Assignment -SJM & MAG#page1.tif
- source=ISO-P1742PCT IP102 Executed Assignment -SJM & MAG#page2.tif
- source=ISO-P1742PCT IP102 Executed Assignment -SJM & MAG#page3.tif
- source=ISO-P1742PCT IP102 Executed Assignment -BW#page1.tif
- source=ISO-P1742PCT IP102 Executed Assignment -BW#page2.tif
- source=ISO-P1742PCT IP102 Executed Assignment -BW#page3.tif
- source=ISO-P1742PCT IP101 Assignment SK v2-Updated#page1.tif
- source=ISO-P1742PCT IP101 Assignment SK v2-Updated#page2.tif
- source=ISO-P1742PCT IP101 Assignment SK v2-Updated#page3.tif
- source=ISO-P1742PCT IP101 Assignment SK v2-Updated#page4.tif

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3738069

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
STEVEN JAMES MOSS	12/03/2015
MATTHEW ALAN GREGORY	12/03/2015
BARRIE WILKINSON	12/10/2015
STEVEN KENDREW	12/09/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ISOMERASE
<b>Street Address:</b>	SUITE 9, SCIENCE VILLAGE
<b>Internal Address:</b>	CHESTERFORD RESEARCH PARK
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	CB10 1XL
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14903190
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(215)563-4044
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(215) 563-4100
<b>Email:</b>	docketclerk@ddhs.com
<b>Correspondent Name:</b>	ROBERT C. NETTER, JR., PH.D., J.D.
<b>Address Line 1:</b>	1601 MARKET STREET
<b>Address Line 2:</b>	SUITE 2400
<b>Address Line 4:</b>	PHILADELPHIA, PENNSYLVANIA 19103
<b>ATTORNEY DOCKET NUMBER:</b>	5078-P06279US00
<b>NAME OF SUBMITTER:</b>	ROBERT C. NETTER, JR., PH.D., J.D.
<b>SIGNATURE:</b>	/Robert C. Netter, Jr./
<b>DATE SIGNED:</b>	02/12/2016
<b>Total Attachments: 11</b>	

## CONFIRMATORY ASSIGNMENT

WHEREAS WE **Steven James MOSS** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom, **Matthew Alan GREGORY** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom and **Barrie WILKINSON** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom (hereinafter called the "Inventors") have invented or discovered "**NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION**" (hereinafter called the "Invention") for which a PCT patent application was filed at the European Patent Office as Receiving Office under number PCT/GB2014/052094 on 9<sup>th</sup> July 2014 claiming priority to a patent application filed at the Intellectual Property Office in the United Kingdom under number 1312318.7 on 9<sup>th</sup> July 2013 (hereinafter called the "Applications");

WHEREAS **Steven James MOSS**, **Matthew Alan GREGORY** and **Barrie WILKINSON** were employed at the time of making of the Invention by **Isomerase Therapeutics Ltd.** whose registered address is Science Village, Chesterford Research Park, Cambridge CB10 1XL, United Kingdom (English company number 08335008, hereinafter called "ISOMERASE") and whereas the invention was made in the course of employment under circumstances whereby an invention may reasonably be expected to result and all rights in and to the invention are assigned to **ISOMERASE** by operation of law, specifically s39 of the Patents Act 1977, and moreover by virtue of a specific assignment clause in their contracts of employment;

WHEREAS the **Inventors** and **ISOMERASE** have authorised and requested the filing of the **Applications**;


NOW, THEREFORE, to all whom it may concern be it known that for consideration of the sum of £1 (one pound sterling) or other valuable consideration, the sufficiency of which is hereby acknowledged, we the **Inventors** hereby confirm the ownership by **ISOMERASE** of the **Invention** and the **Applications** and hereby assign and transfer to **ISOMERASE** all ownership right, title and interest in and to the **Invention** and the **Applications** and to any priority rights for all territories of the world in respect of the **Invention** and the **Applications** and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension, or re-issue thereof, or Supplementary Protection Certificate based

thereon, and we the **inventors** hereby authorise and request any patent arising therefrom in any territory of the world be issued to **ISOMERASE**;

**AND** we the **inventors** for ourselves and our respective executors and legal representatives hereby agree to provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **ISOMERASE** its successors and assigns, the whole right, title and interest in and to the **Invention** and the **Applications**.

**IN WITNESS** whereof and with effect from 9<sup>th</sup> July 2013 the **inventors** and **ISOMERASE** through its authorised official have hereunto set their respective hands:


**SIGNED by Steven James MOSS**



.....

Date 3<sup>rd</sup> December 2015


in the presence of:



.....

NIGEL CONTER  
SAPPHIRE WOODS  
ESSEX

**SIGNED by Matthew Alan GREGORY**



.....

Date 3<sup>rd</sup> December 2015

in the presence of:



.....

JAMES  
SALTON  
CAMBRIDGE

**SIGNED by Barrie WILKINSON**

.....

Date.....

in the presence of:

.....

**SIGNED by ISOMERASE:**

*Quilley*  
.....

Date *18/12/2015*.....

Name: *M. GREEN*.....

Capacity: *CEO*.....

## CONFIRMATORY ASSIGNMENT

**WHEREAS WE Steven James MOSS** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom, **Matthew Alan GREGORY** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom and **Barrie WILKINSON** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom (hereinafter called the "**Inventors**") have invented or discovered "**NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION**" (hereinafter called the "**Invention**") for which a PCT patent application was filed at the European Patent Office as Receiving Office under number PCT/GB2014/052094 on 9<sup>th</sup> July 2014 claiming priority to a patent application filed at the Intellectual Property Office in the United Kingdom under number 1312318.7 on 9<sup>th</sup> July 2013 (hereinafter called the "**Applications**");

**WHEREAS Steven James MOSS, Matthew Alan GREGORY and Barrie WILKINSON** were employed at the time of making of the **Invention** by **Isomerase Therapeutics Ltd.** whose registered address is Science Village, Chesterford Research Park, Cambridge CB10 1XL, United Kingdom (English company number 08335008, hereinafter called "**ISOMERASE**") and whereas the invention was made in the course of employment under circumstances whereby an invention may reasonably be expected to result and all rights in and to the invention are assigned to **ISOMERASE** by operation of law, specifically s39 of the Patents Act 1977, and moreover by virtue of a specific assignment clause in their contracts of employment;

**WHEREAS the Inventors and ISOMERASE** have authorised and requested the filing of the **Applications**;

**NOW, THEREFORE,** to all whom it may concern be it known that for consideration of the sum of £1 (one pound sterling) or other valuable consideration, the sufficiency of which is hereby acknowledged, we the **Inventors** hereby confirm the ownership by **ISOMERASE** of the **Invention** and the **Applications** and hereby assign and transfer to **ISOMERASE** all ownership right, title and interest in and to the **Invention** and the **Applications** and to any priority rights for all territories of the world in respect of the **Invention** and the **Applications** and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension, or re-issue thereof, or Supplementary Protection Certificate based

thereon, and we the **Inventors** hereby authorise and request any patent arising therefrom in any territory of the world be issued to **ISOMERASE**;

**AND** we the **Inventors** for ourselves and our respective executors and legal representatives hereby agree to provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **ISOMERASE** its successors and assigns, the whole right, title and interest in and to the **Invention** and the **Applications**.

**IN WITNESS** whereof and with effect from 9<sup>th</sup> July 2013 the **Inventors** and **ISOMERASE** through its authorised official have hereunto set their respective hands:

**SIGNED** by **Steven James MOSS**

..... Date.....

in the presence of:

.....

**SIGNED** by **Matthew Alan GREGORY**


..... Date.....

in the presence of:

.....



SIGNED by **Barrie WILKINSON**



Date 10/12/2015

in the presence of:

Tom Scott

THOMAS SCOTT 10/12/15

SIGNED by ISOMERASE:



Date 18<sup>th</sup> December 2015

Name: M. G. G. G.

Capacity: CEO

## CONFIRMATORY ASSIGNMENT

**WHEREAS I Steven KENDREW** a British citizen of 6 Cowper Road, Cambridge, CB1 3SN, United Kingdom (hereinafter called the "**Inventor**") have invented or discovered some or all of "**NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION**" (hereinafter called the "**Invention**") for which a PCT patent application was filed at the European Patent Office as Receiving Office under number PCT/GB2014/052094 on 9<sup>th</sup> July 2014 claiming priority to a patent application filed at the Intellectual Property Office in the United Kingdom under number 1312318.7 on 9<sup>th</sup> July 2013 (hereinafter called the "**Applications**");

**WHEREAS Steven KENDREW** was employed at the time of making of the **Invention** by **Biotica Technology Ltd.** whose registered address is Riverside 3, Granta Park, Cambridge, CB21 6AD, UK (English company number 03243295, hereinafter called "**BIOTICA**") and whereas the invention was made in the course of employment under circumstances whereby an invention may reasonably be expected to result and all rights in and to the invention are assigned to **BIOTICA** by operation of law, specifically s39 of the Patents Act 1977, and moreover by virtue of a specific assignment clause in his contract of employment;

**WHEREAS Isomerase Therapeutics Ltd.** whose registered address is Suite 9, Science Village, Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom (English company number 08335008, hereinafter called "**ISOMERASE**") has acquired all rights to this invention from **BIOTICA** by virtue of an agreement dated 15<sup>th</sup> March 2013;

**WHEREAS the Inventor and ISOMERASE** have authorised and requested the filing of the **Applications**;


**NOW, THEREFORE,** to all whom it may concern be it known that for consideration of the sum of £1 (one pound sterling) or other valuable consideration, the sufficiency of which is hereby acknowledged, I the **Inventor** hereby confirm the ownership by **ISOMERASE** of the **Invention** and the **Applications** and hereby assign and transfer to **ISOMERASE** all ownership right, title and interest in and to the **Invention** and the **Applications** and to any priority rights for all territories of the world in respect of the **Invention** and the **Applications** and in and to any divisional application, continuation

or continuation in part application thereof, and in and to any extension, or re-issue thereof, or Supplementary Protection Certificate based thereon, and I the **Inventor** hereby authorise and request any patent arising therefrom in any territory of the world be issued to **ISOMERASE**;

**AND** I the **Inventor** for myself and my executors and legal representatives hereby agree to provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **ISOMERASE** its successors and assigns, the whole right, title and interest in and to the **Invention** and the **Applications**.


**IN WITNESS** whereof and with effect from 9<sup>th</sup> July 2013 the **Inventor** and **ISOMERASE** through its authorised official have hereunto set their respective hands:

**SIGNED** by **Steven KENDREW**


  
.....

Date 21/3/16 .....

in the presence of:

  
.....

**SIGNED** by **ISOMERASE**:

  
.....

Date..... 24/3/16 .....

Name: ..... MATTHEW GREGORY .....

Capacity..... CEO .....

